<p><strong>Articore Group Limited</strong> (ASX:ATG) 的股票在经历了一段动荡期后，最近一个月表现非常出色，涨幅达到 28%。回顾过去一年，尽管最近 30 天表现强劲，但过去 12 个月的 21% 涨幅也算不错。</p>
<p>尽管价格大幅反弹，Articore Group 的市销率（&#34;P/S&#34;）为 0.2 倍，与澳大利亚的多元零售行业相比，仍然显得具有吸引力，因为该行业约有一半的公司市销率超过 0.8 倍，甚至市销率超过 3 倍的情况也相当普遍。不过，我们需要深入分析，以确定市销率降低是否有合理的依据。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行探索。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
<p>查看我们对 Articore Group 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/36276704-ps-multiple-vs-industry-1-dark-2/1769112109599?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/36276704-ps-multiple-vs-industry-1-dark-2/1769112109599"/></p>
<p>ASX:ATG 市销率与行业比较 2026 年 1 月 22 日</p>
<h3>Articore Group 的市销率对股东意味着什么？</h3>
<p>最近，Articore Group 的表现不佳，其收入下降与其他公司相比显得尤为糟糕，后者的收入平均有所增长。似乎许多人预计糟糕的收入表现将持续，这抑制了市销率。因此，尽管可以说该股票便宜，但投资者希望在看到其价值之前，能够看到改善的迹象。</p>
<p>如果您想了解分析师对未来的预测，可以查看我们对 Articore Group 的 <strong>免费</strong> 报告。</p>
<h2>收入增长指标告诉我们关于低市销率的什么？</h2>
<p>有一个内在假设，即公司应该表现不如行业，才能使像 Articore Group 这样的市销率被视为合理。</p>
<p>首先回顾一下，去年公司的收入增长并不令人兴奋，出现了令人失望的 11% 的下降。过去三年也不太好，公司总共减少了 24% 的收入。因此，不幸的是，我们必须承认公司在这段时间内未能很好地实现收入增长。</p>
<p>展望未来，预计未来三年将带来减少的回报，收入预计每年下降 3.2%，这是由关注该公司的双重分析师估算的。在行业其他公司预计每年增长 6.0% 的情况下，这并不理想。</p>
<p>鉴于此，Articore Group 的市销率低于大多数其他公司是可以理解的。不过，考虑到收入在下降，市销率是否已经触底并没有保证。如果公司不改善其收入增长，市销率可能会进一步下降。</p>
<h2>关键要点</h2>
<p>Articore Group 的股价最近飙升，但其市销率仍然保持在适中水平。一般来说，我们倾向于将市销率的使用限制在评估市场对公司整体健康状况的看法上。</p>
<p>显然，Articore Group 由于预期收入下滑而维持低市销率是显而易见的。由于行业内其他公司预计收入增长，Articore Group 的糟糕前景也为其低市销率提供了合理性。在这种情况下，很难看到股价在近期内强劲上涨。</p>
<p>始终需要考虑投资风险的潜在威胁。我们已识别出 <strong>Articore Group 的 1 个警示信号</strong>，理解这一点应成为您投资过程的一部分。</p>
<p>如果您对 Articore Group 的业务实力 <strong>不确定</strong>，何不探索我们互动式的股票列表，寻找一些您可能错过的基本面良好的其他公司呢？</p>

ATRC

<p>Articore Group Limited (ASX:ATG) 的股票最近上涨了 28%，但其市销率（P/S）仍然较低，为 0.2 倍，表明可能被低估。尽管过去一年增长了 21%，但公司在收入方面面临困境，去年收入下降了 11%，三年来下降了 24%。分析师预测，未来每年收入将进一步减少 3.2%，而行业预计增长为 6%。这种疲软的前景解释了低市销率，使得近期股价大幅上涨的可能性不大</p>

<p><strong>Articore Group Limited</strong> (ASX:ATG) shares have had a really impressive month, gaining 28% after a shaky period beforehand. Looking further back, the 21% rise over the last twelve months isn't too bad notwithstanding the strength over the last 30 days.</p>
<div class="lb-trans"><p><strong>Articore Group Limited</strong> (ASX:ATG) 的股票在经历了一段动荡期后，最近一个月表现非常出色，涨幅达到 28%。回顾过去一年，尽管最近 30 天表现强劲，但过去 12 个月的 21% 涨幅也算不错。</p>
</div><p>In spite of the firm bounce in price, Articore Group's price-to-sales (or &#34;P/S&#34;) ratio of 0.2x might still make it look like a buy right now compared to the Multiline Retail industry in Australia, where around half of the companies have P/S ratios above 0.8x and even P/S above 3x are quite common. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.</p>
<div class="lb-trans"><p>尽管价格大幅反弹，Articore Group 的市销率（&#34;P/S&#34;）为 0.2 倍，与澳大利亚的多元零售行业相比，仍然显得具有吸引力，因为该行业约有一半的公司市销率超过 0.8 倍，甚至市销率超过 3 倍的情况也相当普遍。不过，我们需要深入分析，以确定市销率降低是否有合理的依据。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行探索。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
</div><p>Check out our latest analysis for Articore Group</p>
<div class="lb-trans"><p>查看我们对 Articore Group 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/36276704-ps-multiple-vs-industry-1-dark-2/1769112109599" alt="" original-src="https://images.simplywall.st/asset/chart/36276704-ps-multiple-vs-industry-1-dark-2/1769112109599"/></p>
<p>ASX:ATG Price to Sales Ratio vs Industry January 22nd 2026</p>
<div class="lb-trans"><p>ASX:ATG 市销率与行业比较 2026 年 1 月 22 日</p>
</div><h3>What Does Articore Group's P/S Mean For Shareholders?</h3>
<div class="lb-trans"><h3>Articore Group 的市销率对股东意味着什么？</h3>
</div><p>Articore Group hasn't been tracking well recently as its declining revenue compares poorly to other companies, which have seen some growth in their revenues on average. It seems that many are expecting the poor revenue performance to persist, which has repressed the P/S ratio. So while you could say the stock is cheap, investors will be looking for improvement before they see it as good value.</p>
<div class="lb-trans"><p>最近，Articore Group 的表现不佳，其收入下降与其他公司相比显得尤为糟糕，后者的收入平均有所增长。似乎许多人预计糟糕的收入表现将持续，这抑制了市销率。因此，尽管可以说该股票便宜，但投资者希望在看到其价值之前，能够看到改善的迹象。</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on Articore Group.</p>
<div class="lb-trans"><p>如果您想了解分析师对未来的预测，可以查看我们对 Articore Group 的 <strong>免费</strong> 报告。</p>
</div><h2>What Are Revenue Growth Metrics Telling Us About The Low P/S?</h2>
<div class="lb-trans"><h2>收入增长指标告诉我们关于低市销率的什么？</h2>
</div><p>There's an inherent assumption that a company should underperform the industry for P/S ratios like Articore Group's to be considered reasonable.</p>
<div class="lb-trans"><p>有一个内在假设，即公司应该表现不如行业，才能使像 Articore Group 这样的市销率被视为合理。</p>
</div><p>Taking a look back first, the company's revenue growth last year wasn't something to get excited about as it posted a disappointing decline of 11%. The last three years don't look nice either as the company has shrunk revenue by 24% in aggregate. So unfortunately, we have to acknowledge that the company has not done a great job of growing revenue over that time.</p>
<div class="lb-trans"><p>首先回顾一下，去年公司的收入增长并不令人兴奋，出现了令人失望的 11% 的下降。过去三年也不太好，公司总共减少了 24% 的收入。因此，不幸的是，我们必须承认公司在这段时间内未能很好地实现收入增长。</p>
</div><p>Turning to the outlook, the next three years should bring diminished returns, with revenue decreasing 3.2% per annum as estimated by the dual analysts watching the company. That's not great when the rest of the industry is expected to grow by 6.0% each year.</p>
<div class="lb-trans"><p>展望未来，预计未来三年将带来减少的回报，收入预计每年下降 3.2%，这是由关注该公司的双重分析师估算的。在行业其他公司预计每年增长 6.0% 的情况下，这并不理想。</p>
</div><p>In light of this, it's understandable that Articore Group's P/S would sit below the majority of other companies. Nonetheless, there's no guarantee the P/S has reached a floor yet with revenue going in reverse. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth.</p>
<div class="lb-trans"><p>鉴于此，Articore Group 的市销率低于大多数其他公司是可以理解的。不过，考虑到收入在下降，市销率是否已经触底并没有保证。如果公司不改善其收入增长，市销率可能会进一步下降。</p>
</div><h2>The Key Takeaway</h2>
<div class="lb-trans"><h2>关键要点</h2>
</div><p>Articore Group's stock price has surged recently, but its but its P/S still remains modest. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.</p>
<div class="lb-trans"><p>Articore Group 的股价最近飙升，但其市销率仍然保持在适中水平。一般来说，我们倾向于将市销率的使用限制在评估市场对公司整体健康状况的看法上。</p>
</div><p>It's clear to see that Articore Group maintains its low P/S on the weakness of its forecast for sliding revenue, as expected. As other companies in the industry are forecasting revenue growth, Articore Group's poor outlook justifies its low P/S ratio. It's hard to see the share price rising strongly in the near future under these circumstances.</p>
<div class="lb-trans"><p>显然，Articore Group 由于预期收入下滑而维持低市销率是显而易见的。由于行业内其他公司预计收入增长，Articore Group 的糟糕前景也为其低市销率提供了合理性。在这种情况下，很难看到股价在近期内强劲上涨。</p>
</div><p>It's always necessary to consider the ever-present spectre of investment risk. We've identified <strong>1 warning sign with Articore Group</strong>, and understanding should be part of your investment process.</p>
<div class="lb-trans"><p>始终需要考虑投资风险的潜在威胁。我们已识别出 <strong>Articore Group 的 1 个警示信号</strong>，理解这一点应成为您投资过程的一部分。</p>
</div><p>If you're <strong>unsure about the strength of Articore Group's business</strong>, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.</p>
<div class="lb-trans"><p>如果您对 Articore Group 的业务实力 <strong>不确定</strong>，何不探索我们互动式的股票列表，寻找一些您可能错过的基本面良好的其他公司呢？</p>
</div>

Articore Group Limited (ASX:ATG) 即便股价上涨了 28%，仍因增长不足而受到限制